Your Health, We Care
Release date: 2024-08-26 17:12:12 Recommended: 126
Alpelisib was approved by the FDA in 2019 for the treatment of breast cancer patients with HR/HER2- and PIK3CA mutations. By inhibiting the PI3K signaling pathway, Alpelisib effectively delays disease progression and brings new hope for treatment in patients with advanced breast cancer.
In terms of therapeutic effect, Alpelisib has shown significant efficacy in breast cancer targeting PIK3CA mutations, which can effectively delay disease progression.
In patients with PIK3CA mutations, treatment with apelix-plus-fulvestrant has shown some efficacy, particularly with regard to PFS and ORR.
No significant therapeutic benefit was observed in patients whose tumors were not found to have PIK3CA mutations in their tumors, which further supports the specificity of PIK3CA mutations as therapeutic targets.
Alpelisib has shown promising results in patients with PIK3CA-mutated breast cancer. Here's a closer look at what to look out for.
When using apelix, pay special attention to the following.
Pay close attention to symptoms of diarrhea and colitis, such as abdominal pain, mucus or bloody stools. Depending on the severity of symptoms, medications may need to be adjusted or stopped, fluid intake may be increased during diarrhea, and doctors may need to be informed.
Patients should be aware of the signs and symptoms of severe hypersensitivity reactions. Apelix should be discontinued immediately if symptoms develop to avoid further health risks.
Precautions cover side effects and management measures to focus on when using Alpelisib. Next, the interaction of Alpelisib with other drugs will be explored to further optimize the treatment plan.
Drug interactions are an important factor in optimizing treatment with apelix, and understanding interactions with other drugs can avoid potential risks and improve drug efficacy.
Concomitant use with BCRP inhibitors may result in elevated concentrations of Alpelisib, increasing the risk of toxicity. Concomitant use of BCRP inhibitors is recommended to be avoided. If this cannot be avoided, the patient needs to be closely observed for adverse effects.
Understanding drug interactions is critical to the smooth administration of Alpelisib therapy. Please communicate with your healthcare provider during the medication process to ensure that your treatment goes smoothly.
[Warm tips] During the use of Alpelisib, please communicate with your doctor regularly and pay close attention to possible side effects and drug interactions. If you have any discomfort or questions, please consult a medical professional promptly.
